Jonathan Teyan, President and CEO of the Associated Medical Schools of New York (AMSNY) and New York State Academic Dental Centers (NYSADC), testified today before the Assembly Standing Committee on Economic Development, Job Creation, Commerce and Industry; the Assembly Standing Committee on Small Business; and the Legislative Commission on Skills Development and Career Education.
Teyan highlighted biomedical research’s role in creating jobs, attracting investment and improving health outcomes while urging New York State to strengthen its investments as other states and countries intensify efforts to recruit leading scientists.
The testimony included the following:
“New York State is the second leading recipient of funding from the National Institutes of Health, with $3.5 billion awarded to New York scientists in 2025—primarily, but not exclusively, at our academic institutions—and directly supporting 35,000 jobs.”
“Federal funding, along with state and local investments, has translated to direct results in the private sector, with nearly 6,000 life sciences companies—a 20% growth over the past five years—attracting $3.6 billion in venture capital investment and employing more than 160,000 New Yorkers.”
“The competition for scientists has escalated dramatically over the last two years. Other states and global competitors have launched multibillion-dollar campaigns to recruit scientists. Given the instability of federal research funding since early 2025, New York’s scientists—particularly our early-career researchers—are a prime target for these recruitment efforts.”
Teyan pointed to the New York Fund for Innovation in Research and Scientific Talent, or NYFIRST, as a proven example of the economic impact of state investment in biomedical research.
Since 2018, $17.7 million committed by New York State through NYFIRST has generated $191 million in additional research spending—a nearly 11-to-1 return on the state’s investment. The program has helped New York institutions recruit or retain 18 leading scientists, create 202 jobs and file 29 patent applications. NYFIRST-supported research has also led to the launch of two spinout companies.
In addition to continued support for NYFIRST, Teyan urged the creation of a state-funded Empire Biomedical Research Institute. Proposed by a coalition of more than 40 organizations representing New York’s scientific, higher education, healthcare, business and economic-development communities, EBRI would help the state retain and recruit scientists, protect federally funded research and expand New York’s innovation economy.
The EBRI coalition recommends an initial investment of $500 million over two years to establish the institute’s infrastructure, recruit and retain biomedical researchers and provide financial relief for federally funded projects. The coalition ultimately recommends a $6 billion investment over 10 years, including both capital and operating support.
“Despite the clear economic and health benefits, New York State’s commitments to biomedical research have significantly lagged our closest U.S. competitors in nominal and per-capita investments,” Teyan testified.
“A fully funded EBRI would enhance the development of our scientific workforce while accelerating the growth of New York’s innovation economy and ensuring access to the highest-quality healthcare through new technologies, treatments and cures for all New Yorkers.”